2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Hybrid strategy of coronary atherosclerosis characterization with T1-weighted MRI and CT angiography to noninvasively predict periprocedural myocardial injury

Matsumoto H, Higuchi S, Li D, Tanisawa H, Isodono K, Irie D, Ohya H, Kitamura R, Kaneko K, Nakazawa M, Suzuki K, Komori Y, Hondera[...]

Repercussions of the COVID- 19 pandemic on maternal and congenital syphilis in South Brazil: a time series analysis 2010-2022

Echegaray F, Hernandez CJ, Sundar KG, Yang LZ, Cambou MC, Segura ER, de Melo MG, Santos BR, Dos Santos Varella IR, Nielsen-Saines K. Repercussions of[...]

Disseminated coccidioidomycosis presenting as eosinophilic ascites

Fetters KB, Fernandez-Hazoury D, Grujic S, Lee P. Disseminated coccidioidomycosis presenting as eosinophilic ascites. BMJ Case Rep. 2025 Apr 15;18(4):e263734. doi: 10.1136/bcr-2024-263734. PMID: 40234081.